|
|
Article: FDA APPROVES TAGAMET FOR PREVENTION OF UPPER GI BLEEDING IN CRITICALLY ILL (Product Announcement)
- Article from:
- PR Newswire
- Article date:
- December 9, 1991
CopyrightCOPYRIGHT 1991 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FDA APPROVES TAGAMET FOR PREVENTION OF UPPER GI BLEEDING IN
CRITICALLY ILL
NEW ORLEANS, Dec. 9 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approvced Tagamet(R) (cimetidine), administered 50 mg/hour (1200 mg/day) by continuous intravenous infusion, for the prevention of upper gastrointestinal (GI) bleeding in critically ill hospitalized patients, SmithKline Beecham announced today. Tagamet is the first H2 antagonist with this indication.
For reasons that are not completely clear, critically ill hospitalized patients are at high risk of developing upper gastrointestinal tract damage as a complication of severe ...
Related newspaper, magazine, and journal articles:
|
|
Article: Glaxo Wellcome and SmithKline Beecham Merger ...
PR Newswire;
December 18, 2000 ;
700+ words
... ... Glaxo Wellcome (NYSE: GLX) and SmithKline Beecham (NYSE: SBH) today announce that ... GlaxoSmithKline. Glaxo Wellcome and SmithKline Beecham have now obtained all regulatory ... secure FTC approval for the merger, SmithKline Beecham has agreed to divest the anti-emetic ...
|
|